Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsFRA:01P +0.49%95 Net Margin % is 17.16% as of Jun. 2026, which is 12% above its 10-year median of 15.35. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 90.15% on this metric.
The historical rank and industry rank for Medpace Holdings's Net Margin % or its related term are showing as below:
FRA:01P'
s Net Margin % Range Over the Past 10 Years
Min: 3.18 Med: 15.35 Max: 19.17
Current: 17.67
FRA:01P's Net Margin % is ranked better than 90.15% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.69
vs FRA:01P: 17.67
Medpace Holdings (FRA:01P) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Medpace Holdings Net Margin % Related Terms
Medpace Holdings Net Margin % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:01P vs ICLR, RVTY, CRL: Net Margin % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (FRA:01P) has a Net Margin % of 17.16% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Medpace Holdings and its competitors. This is 12% above median its historical median of 15.35. Over the past decade, Medpace Holdings' Net Margin % has ranged from 3.18 to 19.17. According to the industry distribution chart, Medpace Holdings ranks #20 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 9.9%.
Is Medpace Holdings' Net Margin % too high?
Medpace Holdings' current Net Margin % of 17.16% is 12% above median its 10-year median of 15.35. Over the past 10 years, this metric has ranged from a low of 3.18 to a high of 19.17. Based on the distribution chart, Medpace Holdings ranks #20 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Net Margin % compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #20 out of 203 companies for Net Margin %. This places Medpace Holdings in the top 10% of its industry — outperforming the majority of peers. Historically, Medpace Holdings' own Net Margin % has ranged from 3.18 to 19.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Net Margin % is 17.16%, which is 12% above median its own 10-year median of 15.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current Net Margin % is 17.16%, which is 12% above median its 10-year median of 15.35. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current Net Margin % is 17.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
Net Margin %: 17.16% (12% above median its 10-year median of 15.35)
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
